AKRUTI Kendra aspires inclusive technological growth
Visakhapatnam: In a significant step towards enhancing technology transfer for societal benefit, the Bhabha Atomic Research Centre (BARC) signed a memorandum of understanding (MoU) with the GITAM Technology Enabling Centre (GTEC) in Visakhapatnam here on Thursday.
The collaboration aims to establish an AKRUTI Kendra on the campus which will serve as a platform for technology translation and commercialisation, particularly for micro, small, and medium enterprises (MSMEs) and local industries.
The AKRUTI programme, a flagship initiative by DAE-BARC, focuses on deploying advanced atomic research technologies for societal applications, particularly in rural and urban development.
The MoU was exchanged between institution's Registrar D Gunasekharan and Department of Atomic Energy (DAE) Technology Transfer and Collaboration Division in the presence of the institution's Vice-Chancellor Errol D'Souza, BARC Technology Transfer and Collaboration Division AKRUTI Group Leader Bharati A Bhalera, among others.
The newly-established kendra at the institution will act as a catalyst in enabling access to BARC-developed technologies, fostering innovation and bridging the gap between research and industry needs.
This strategic partnership underscores the shared commitment of BARC and the institution to promote inclusive technological growth and create sustainable solutions for national development.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 days ago
- Time of India
Explore MBBS, global higher education opportunities at seminar on Sunday
Pune: Students aspiring for careers in medicine or aiming to pursue higher education abroad can explore their options at a seminar organised by The Times of India at Dr Shamrao Kalmadi Junior College Auditorium in Erandwane on Sunday. This event offers practical guidance on both Indian MBBS admissions and opportunities for bachelor's and master's programmes in the US and Germany. The seminar, open to students and parents, will feature two informative sessions led by expert Tushar Deoras, a former BARC scientist, and chairman of Astute Academy. He has 30 years of experience guiding students toward affordable, quality education. The second session will take students through on securing admission to top-ranked universities abroad. The first session called 'Indian & International MBBS Admissions' will be held between 10.30am and 12.30pm. It will focus on the admission process, particularly for students with NEET scores as low as 200. It will talk about merit-based admissions without donations or management quotas and explain how students can secure seats in private colleges by paying govt-mandated fees. The session will also introduce affordable medical education pathways to the US via structured partnerships between Indian and American universities. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch CFD với công nghệ và tốc độ tốt hơn IC Markets Đăng ký Undo Students who want to pursue a bachelor's and master's degree in the US and Germany will have a session between 12.30pm and 2pm on securing admission to top-ranked universities, including Ivy League institutions like Harvard, MIT, Yale, Stanford, and Germany's renowned technical universities. This session will be valuable for those exploring 100% scholarships in the US and tuition-free programmes in Germany. The talk will walk attendees through every step of the application process, from academic criteria and language requirements to financial planning and visa documentation. Students are encouraged to register in advance using the QR code provided and arrive on time. Entry is open for both sessions, and attendees are welcome to participate in one or both, depending on their interests. For aspiring doctors and global scholars, this seminar could be a crucial step in making an informed, future-ready education choices. Get the latest lifestyle updates on Times of India, along with Eid wishes , messages , and quotes !
Time of India
2 days ago
- Time of India
GITAM holds spl graduation ceremony for int'l students
Visakhapatnam: Gitam Deemed to be University conducted its sixth special graduation ceremony for international students from Kenya, Rwanda, Bhutan, Nigeria, Nepal, Ethiopia, Uganda, and other nations. As many as 60 international students completed their academic programs in engineering, science, pharmacy, paramedical sciences, and management this year at Gitam. Addressing the gathering, registrar Prof D Gunasekharan highlighted the growing appeal of India's higher education system among international students. "India's educational landscape rich in diversity, culture, and history makes it a preferred global destination for academic pursuits. Education plays a critical role in fostering economic growth and development across nations," said Prof Gunasekharan. GITAM School of Pharmacy principal Prof Srinivas urged graduates to apply their acquired knowledge towards the development of human capital in their home countries. He encouraged them to pursue research-oriented careers to better serve society. GIMSR biochemistry department Prof Dr K Viswa Kalyan congratulated the students and encouraged them to continue learning in order to stay competitive in today's world. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch CFD với công nghệ và tốc độ tốt hơn IC Markets Đăng ký Undo Director of international affairs Dr. KPC Kishan said that over 400 students from 43 countries are currently enrolled across various programs at Gitam. He acknowledged the Union govt's 'Study in India' initiative for promoting Indian higher education on the global stage. Get the latest lifestyle updates on Times of India, along with Eid wishes , messages , and quotes !
Mint
3 days ago
- Mint
Despite trade war, US drug companies turn to China for key cancer treatments
The drug industry has spent months going along with the Trump administration's efforts to move manufacturing and investment into the U.S., and to disentangle the U.S. and Chinese economies. A long list of big pharmaceutical firms have committed tens of billions of dollars to factories and research facilities in the U.S. In the past few months, though, U.S. pharma companies have simultaneously supercharged their interest in China-based biotechs, announcing what are likely to be the biggest deals ever for the rights to experimental medicines invented by Chinese companies. So far, the Trump administration has been silent on the deals, which are worth around $25 billion in upfront and potential milestone payments and seem to fly in the face of White House policy. The deals could one day result in new options for sick patients, but they also pose a major risk to U.S. biotech firms. The domestic drug pipeline relies on capital from Big Pharma, and now those funds may be going to start-ups in Shanghai, rather than Cambridge, Mass. The recent deals follow a successful trial result last year by U.S. biotech Summit Therapeutics of a new immunotherapy cancer drug it licensed from Chinese firm Akeso. In the trial, the drug outperformed Merck's top-selling Keytruda, raising hopes that it could prove a major advancement in cancer treatment. Since then, Big Pharma companies have rushed to get their own drugs to compete with Summit's product. There was one deal in November, when Merck licensed an experimental drug from a Chinese drugmaker for around $500 million up front and another $2.7 billion in potential milestone payments. The biggest deals have come in just the past two weeks. In mid May, Pfizer said it would pay the Chinese biotech 3SBio $1.3 billion up front for its own competitor to the Summit drug, plus billions more in potential milestone payments. Pfizer is also making a $100 million equity investment in 3SBio. This past week, Bristol Myers Squibb said it would pay $3.5 billion over the next three years, plus billions more in potential milestone payments, for half the rights to a similar drug developed by a Chinese company called Biotheus, which German biotech BioNTech acquired a few months ago. These numbers would be big for any biotech licensing deal—the drugs remain far from approval. For Chinese-developed drugs, the payment sizes are unprecedented. 'These are pretty sophisticated companies allocating major capital here," says Craig Garthwaite, a professor and director of the program on healthcare at Northwestern University's Kellogg School of Management, of the latest deals. 'It's demonstrating the validity of the science." It's all happening while Big Pharma is doing its best to show the Trump administration that it can adapt to the president's agenda, as the industry seeks to head off threatened tariffs and drug price limits. Eli Lilly, Johnson & Johnson, Bristol Myers, and others have all announced tens of billions of dollars in planned U.S. investments in manufacturing and research facilities this year. The White House didn't respond to a request for comment. Washington has been increasingly anxious about the rapid development of China's biotech ecosystem. The Biosecure Act, which hasn't passed Congress, targets complex drug manufacturing in China, while a recent report commissioned by Congress called on the U.S. to take 'swift action" to compete with the Chinese biotech sector. Amid those stalled efforts, the pace of Chinese biotech innovation is picking up. Until recently, the U.S. drug industry had largely seen Chinese biotechs as a source for cheaper 'me too" assets, which echo but don't duplicate existing medicines. Now, with the latest cancer drug deals, Chinese companies are innovating a new class of drugs that every Big Pharma firm seems to think it needs to get in on. The Summit drug that got investors, analysts, and companies excited last year is known as a PD-1/VEGF bispecific antibody, which combines two proven cancer-fighting tools. Daina Graybosch, an analyst at Leerink Partners, says that companies in the U.S. and Europe have been experimenting with similar combinations, but never tested them in humans. That's because early-stage human tests are cheaper and easier to run in China than the U.S. All but the largest U.S. biotechs generally develop just one or two experimental medicines at a time, while Chinese biotechs of a similar size 'could have a dozen" different drugs in trials, according to Cantor Fitzgerald analyst Li Watsek. The combination cancer drugs ultimately weren't exciting enough for the U.S. biotechs to prioritize. But Chinese companies moved forward with different variations. When Summit and its Chinese partner got promising results on an antibody that combined PD-1 and VEGF, there were multiple other Chinese biotechs with their own PD-1/VEGF combinations ready to of this is great news for the U.S. biotech sector, which has been battered in recent years by declining share prices, cash shortfalls, and other challenges. Over the past 12 months, the SPDR S&P Biotech exchange-traded fund is down 11.5%, versus a gain of 11.7% for the S&P 500. Watsek says that part of the problem for investors is that it's hard to know what Chinese biotechs are actually working on. 'Right now it's a little bit of a black box, because a lot of these Chinese companies, they may have assets, but it's impossible to track," she says. 'There could be a dozen molecules that are in development that you may not have even heard of." Over the long term, the worries get potentially more complex. 'At some point, it's going to get terminal velocity, and we're going to have a very dangerous competitor next to us," says Joseph Grogan, a senior policy official during the first Trump administration who is now a nonresident senior scholar at the USC Schaeffer Institute. 'If the Chinese establish the flywheel of the ecosystem that we built—of private-sector companies, research and development, government support, and strong but prudent regulatory foundation—then we're cooked." Write to Josh Nathan-Kazis at
